<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5160">
  <stage>Registered</stage>
  <submitdate>16/09/2015</submitdate>
  <approvaldate>16/09/2015</approvaldate>
  <nctid>NCT02553772</nctid>
  <trial_identification>
    <studytitle>A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>11182X-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dry Eye Syndromes</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Carboxymethylcellulose Based Eye Drop
Treatment: drugs - Carboxymethylcellulose Sodium 0.5%

Experimental: Carboxymethylcellulose Based Eye Drop - Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.

Active Comparator: REFRESH OPTIVE® ADVANCED - Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.


Treatment: drugs: Carboxymethylcellulose Based Eye Drop
Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.

Treatment: drugs: Carboxymethylcellulose Sodium 0.5%
Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline in the Ocular Surface Disease Index© (OSDI©) Score on a 5-Point Scale</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Tear Break-up Time (TBUT)</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Corneal Staining on a 6-Point Scale</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Conjunctival Staining on a 6-Point Scale</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in the Schirmer Test</outcome>
      <timepoint>Baseline, Day 90</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Used artificial tears for dry eye

          -  Visual acuity of at least 20/32 (while wearing glasses, if necessary).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Use of contact lenses in the last 3 months, or anticipated use of contact lenses
             during the study

          -  Herpes keratitis in the last 6 months

          -  Cataract surgery, laser-assisted in situ keratomileusis [LASIK], or photorefractive
             keratectomy, within the last 6 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>242</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Department of Optometry &amp; Vision Sciences, The University of Melbourne - Parkville</hospital>
    <hospital>Prof. M.T. Coroneo Pty. Ltd. - Randwick</hospital>
    <hospital>The University of New South Wales School of Optometry and Vision Science - Sydney</hospital>
    <postcode>VIC 3010 - Parkville</postcode>
    <postcode>NSW 2031 - Randwick</postcode>
    <postcode>NSW 2052 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of a new eye drop formulation in patients
      with dry eye disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02553772</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>